Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.

ABSTRACT:

Background

The recent application of gene-sequencing technology has identified many new somatic mutations in patients with myelodysplastic syndromes (MDS). Among them, serine and arginine rich splicing factor 2 (SRSF2) mutations belonging to the RNA splicing pathway were of interest. Many studies have already reported the potential prognostic value of SRSF2 mutations in MDS patients, with controversial results. Therefore, a meta-analysis was performed to investigate their prognostic impact on MDS.

Methods

Databases, including PubMed, Embase and the Cochrane Library, were searched for relevant studies published up to 14 October 2016. Overall survival (OS) was selected as the primary endpoint, and acute myeloid leukemia (AML) transformation was the secondary endpoint. We extra

SUBMITTER: Zheng X 

PROVIDER: S-EPMC5617234 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature